07d0c77d5987f908461f9f7c33741941 .pdf

File information


Original filename: 07d0c77d5987f908461f9f7c33741941.pdf

This PDF 1.7 document has been generated by Adobe InDesign CC 2015 (Macintosh) / Adobe PDF Library 15.0, and has been sent on pdf-archive.com on 15/07/2018 at 08:55, from IP address 178.17.x.x. The current document download page has been viewed 344 times.
File size: 90 KB (2 pages).
Privacy: public file


Download original PDF file


07d0c77d5987f908461f9f7c33741941.pdf (PDF, 90 KB)


Share on social networks



Link to this file download page



Document preview


18th Biennial Jerome P. Richie
Urologic Cancer Course
October 20 – 22, 2016 • Thursday – Saturday
Four Seasons Hotel, Boston, MA
OFFERED BY

Dana-Farber/Brigham and Women’s Cancer Center
COURSE DIRECTORS

Anthony V. D’Amico, MD, PhD, Professor of Radiation Oncology • Philip Kantoff, MD, Professor of Medicine
Adam Kibel, MD, Professor of Surgery • Jerome P. Richie, MD, Professor of Surgery, Emeritus
COURSE DESCRIPTION:
The 18th Biennial Urologic Cancer course educates community-based clinicians on best practices for multi-disciplinary management of genitourinary (GU) cancers.
The course is designed to provide the audience with information regarding current and new treatment and management recommendations of GU cancers and help
them develop strategies to integrate this knowledge into their practices. This course is a live course with didactic lectures, panel discussions, Q&A sessions, and case
reviews and feedback using an audience response system.
COURSE OBJECTIVES:
Upon completion of this course, participants will be able to:
• Apply Level 1 evidence on the use of chemotherapy in men with newly diagnosed metastatic prostate cancer
• Apply Level 1 evidence on the use of active surveillance for men with newly diagnosed low or intermediate risk prostate cancer
• Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced renal cancer
• Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced bladder cancer
• Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced testicular cancer
WHO SHOULD ATTEND:
Urologists, Radiation Oncologists, Medical Oncologists, Primary Care Physicians, physician assistants, nurses and nurse practitioners.
ACCREDITATION:
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy,
hospital, specialty society or college as accredited group learning activities.
Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1
Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be
found at: www.eaccme.eu.
ACGME COMPETENCIES:
This course is designed to meet one or more of the following Accreditation Council of Graduate Medical Education competencies:
Patient Care and Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement and Systems-based Practice.
REGISTRATION INFORMATION:*
Physicians Fee: $650.00, Trainee/Allied Health Professional Fee: $325.00, Residents/Fellows: $325.00.
Registration by credit card (VISA, MasterCard or American Express) or check can be made through Harvard Medical School’s secure online registration system at
https://www.hmscmeregistration.org/urologiccancer2016. Registration by check (draft on a United States bank), please make payable to Harvard Medical School.
Learners who choose to pay by check will be prompted to download an online form to send in with a payment. Telephone or fax registration is not accepted.
Registration with cash payment is not permitted. Upon receipt of your paid registration an email confirmation from the HMS-DCE office will be sent to you. Be sure to
include an email address that you check frequently. Your email address is used for critical information including registration confirmation, evaluation and certificate.
*Processing (non-refundable service fee) $5. All fees shown in USD.
INQUIRIES:
By phone (617-384-8600), Mon - Fri, 9 am to 5 pm (ET) or by email at: ceprograms@hms.harvard.edu.
ONLINE INFORMATION:
To register or view activity information online, visit: https://www.hmscmeregistration.org/urologiccancer2016.
DISCLOSURE POLICY:
Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a
CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify
and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support
received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products
during their presentations.
REFUND POLICY:
Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by
postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will
be issued once the conference has started.
COURSE LOCATION:
All sessions for this course will be held at the Four Seasons Hotel, 200 Boylston Street, Boston, MA (Tel: 617-338-4400).
ACCOMMODATIONS/TRAVEL:
Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration.

For more information and registration: https://www.hmscmeregistration.org/urologiccancer2016

Program Schedule

Course # 732360-1701

THURSDAY, OCTOBER 20, 2016
7:15 am
8:00 am

FRIDAY, OCTOBER 21, 2016
PROSTATE CANCER:
MANAGEMENT OF METASTATIC PROSTATE CANCER
Moderator: Adam Kibel, MD

Registration
Welcome
PROSTATE CANCER: EPIDEMIOLOGY AND OPTIMIZING DETECTION
Moderator: Anthony V. D’Amico, MD, PhD

8:00 am

ADT:for M1 disease Intermittent or Continuous
Speaker: Freddie Hamdy, MD

8:05 am

Epidemiology and Genetics
Speaker: Loreli Mucci, PhD

8:15 am

Docetaxel in hormone naive M1 PC: For all or for some?
Speaker: Christopher Sweeney, MBBS

8:20 am

Evaluating the Novel Diagnostic and Prognostic Tests
and biomakers prior to diagnosis.
Speaker: Adam Kibel, MD

8:30 am

Immunotherapy for Prostate Cancer
Speaker: Lauren Harshman, MD

8:45 am

8:35 am

TRUS guided Prostate Biopsies-How Many? Avoiding complications
Speaker: William DeWolf, MD

Antiresorptives in M1 CRPC
Speaker: Rana McKay, MD

9:00 am

8:50 am

Advances in Multiparametric MRI for Diagnosis and Staging
Speaker: Clare Tempany, MD

Novel Hormone Therapies in M1 CRPC
Speaker: Phillip Kantoff, MD

Image guided prostate Biopsy
Speaker: Peter Pinto, MD

9:15 am

9:05 am

Best use of Radium 223
Speaker: Daniel George, MD

9:30 am

Interpreting Prostate Biopsy Reports
Speaker: Michelle Hirsch, MD, PhD

Break

9:20 am
9:35 am

Panel Discussion and Q&A – Screening and Diagnosis
Moderator: Anthony V. D’Amico, MD, PhD
Drs. Pinto, DeWolf, Tempany, Hirsch, Kibel , Mucci

9:55 am

Break
PROSTATE CANCER: PATIENT SELECTION FOR TREATMENT
Moderator: Anthony V. D’Amico, MD, PhD

10:00 am

The Future-Novel Therapeutics in the Pipeline
Speaker: William Oh, MD

10:15 am

Special Lecture – Clinical Applications of Genomics
to Prostate Cancer – Are we there yet?
Speaker: William Hahn, MD

10:45 am

Panel Discussion and Q&A – Management of Metastatic
Prostate Cancer
Moderator: Adam Kibel, MD
Drs. Oh, George, Kantoff, Sweeney, Harshman, McKay, Hahn, Hamdy

11:30 am

LUNCH

10:30 am

The case for Active Surveillance
Speaker: Anthony Zietman, MD

10:45 am

Biomarkers to select patients for active surveillance vs treatment
Speaker: Freddie Hamdy, MD

11:00 am

Selecting patients for open Radical Prostatectomy
Speaker: Peter Pinto, MD

11:10 am

Selecting patients for Laparoscopic Radical Prostatectomy
Speaker: Douglas Dahl, MD

2:00 pm

Role of Biomarkers in Diagnosis and Follow-up
Speaker: Adam Feldman, MD

11:20 am

Innovations in and patient selection for EBRT
Speaker: Neil Martin, MD, MPH

2:15 pm

Management of Superficial Disease
Speaker: Graeme Steele, MD

11:35 am

ADT duration with RT for Intermediate and High Risk Patients
Speaker: Anthony V. D’Amico, MD, PhD

2:30 pm

Minimally Invasive Treatment of Upper Tract TCC
Speaker: Steven Chang, MD, MS

11:50 am

Management of node positive prostate cancer
Speaker: Phillip Gray, MD

2:45 pm

Radical Cystectomy – Open and robotic techniques
Speaker: Mark Preston, MD, MS

12:05 pm

Panel Discussion and Q&A – Patient Selection
Moderator: Anthony V. D’Amico, MD, PhD
Drs. Pinto, Hamdy, D’Amico, Martin, Gray, Dahl. Zietman

3:00 pm

Urinary Diversion after Cystectomy – Choices and Outcomes
Speaker: Jai Eswara, MD

12:30 pm

LUNCH

3:15 pm

Break

PROSTATE CANCER: STATE OF THE ART AND INNOVATIONS
Moderator: Adam Kibel, MD

3:45 pm

Neoadjuvant and Adjuvant Chemotherapy
Speaker: Daniel George, MD

1:30 pm

Innovations in Radical Prostatectomy
Speaker: Quoc-Dien Trinh, MD

4:00 pm

Bladder Sparing Approaches
Speaker: Jason A. Efstathiou, MD, PhD

1:45 pm

Innovations in Brachytherapy
Speaker: Paul Nguyen, MD

4:15 pm

Chemotherapy for Advanced Disease
Speaker: Joaquim Bellmunt, MD, PhD

2:00 pm

Outcomes of Prostate Cancer Treatment
and Management of Side Effects
Speaker: Peter Chang, MD

4:30 pm

Panel Discussion and Q&A – Bladder Cancer
Moderator: Jerome P. Richie, MD
Drs. George, Feldman, Trinh, Steele, Chang, Bellmunt,
Efstathiou, Harshman

2:15 pm

Novel Approaches for the Unfavorable Risk Patient
Speaker: Mary-Ellen Taplin, MD

5:00pm

Adjourn

2:30 pm

Panel Discussion and Q&A – Innovations
Moderator: Adam Kibel, MD, PhD
Drs.Nguyen, Taplin, Trinh, Pinto, Hamdy

3:00 pm

Break
PROSTATE CANCER: RECURRENT DISEASE
Moderator: Phillip Kantoff, MD

3:30 pm

Adjuvant versus Salvage Radiation
Speaker: Anthony V. D’Amico, MD, PhD

3:45 pm

Management of the Rising PSA-Timing and Optimal ADT
Speaker: William Oh, MD

4:00 pm

Survivorship and Side effects of ADT
Speaker: Matthew Smith, MD, PhD

4:15 pm

Panel and Q&A – Recurrent Disease
Moderator: Phillip Kantoff, MD
Drs. Oh, Smith, D’Amico, Pinto, Hamdy

5:00 pm

Adjourn

Faculty
Clair Beard, MD
Joaquim Bellmunt, MD, PhD
Michael Blute, MD
Peter Chang, MD
Steve Chang, MD, MS
Toni Choueiri, MD
Douglas Dahl, MD
Anthony V. D’Amico, MD, PhD
William DeWolf, MD
Jason A. Efstathiou, MD, PhD
Jai Eswara, MD
Adam Feldman, MD
Daniel George, MD
Phillip Gray, MD
Jerome Groopman, MD
William Hahn, MD
Freddie Hamdy, MD
Lauren Harshman, MD
Michelle Hirsch, MD, PhD
Phillip Kantoff, MD

Adam Kibel, MD, PhD
Neil Martin, MD, MPH
David McDermott, MD
Rana McKay, MD
Loreli Mucci, PhD
Paul Nguyen, MD
William Oh, MD
Aria Olumi, MD
Peter Pinto, MD
Mark Preston, MD
Jerome P. Richie, MD
Matthew Smith, MD, PhD
Christopher Sweeney, MBBS
Graeme Steele, MD
Mary-Ellen Taplin, MD
Clare Tempany, MD
Quoc-Dien Trinh, MD
Kemal Tuncali, MD
Andrew Wagner, MD
Anthony Zietman, MD

1:00 pm

Judah Folkman Lecture
Speaker: Jerome Groopman, MD and Pam Hartzband, MD
BLADDER CANCER
Moderator: Jerome P. Richie, MD

SATURDAY, OCTOBER 22, 2016
RENAL CELL CARCINOMA (RCC)
Moderator: Adam Kibel, MD
8:00 am

Pathology of RCC
Speaker: Michelle Hirsch, MD, PhD

8:15 am

Management of the Small Renal Mass
Speaker: Aria Olumi, MD

8:30 am

Radical or Partial Nephrectomy
Speaker: Andrew Wagner, MD

8:45 am

Laparoscopic and Robotic Radical Nephrectomy
Speaker: Steven Chang, MD, MS

9:00 am

Cryotherapy for Renal Mass
Speaker: Kemal Tuncali, MD

9:15 am

Managing the Primary when Metastatic and Metastatectomy
Speaker: Michael Blute, MD

9:30 am

Treatment of Advanced RCC
Speaker: Toni Choueiri, MD

9:45 am

Sequencing of Therapy in Advanced RCC
Speaker: Daniel George, MD

10:00 am

Novel Approaches for Advanced RCC
Speaker: David McDermott, MD

10:15 am

Panel and Q&A – RCC
Moderator: Adam Kibel, MD
Drs. Blute, McDermott, Choueiri, Tuncali, Hirsch, Olumi, George, Chang

10:45 am

Break
TESTIS CANCER
Moderator: Jerome P. Richie, MD

11:15 am

Management of Seminoma
Speaker: Clair Beard, MD

11:30 am

Management of Stage I non-seminoma
Speaker:Jerome P. Richie, MD

11:45 am

Management of Advanced Disease-Chemotherapy
Speaker: Christopher Sweeney, MBBS

12:00 pm

Panel and Q&A – Testis Cancer
Moderator: Jerome P. Richie, MD
Drs. Sweeney, Beard, Kantoff

12:30 pm

Adjourn

*Please Note: Program changes/substitutions may be made without notice.

For more information and registration: https://www.hmscmeregistration.org/urologiccancer2016


Document preview 07d0c77d5987f908461f9f7c33741941.pdf - page 1/2

Document preview 07d0c77d5987f908461f9f7c33741941.pdf - page 2/2

Related documents


07d0c77d5987f908461f9f7c33741941
2826pathology meetingprogram
14072
er1107
btog 2019 programme v7 draft
813607 jd october2017 3

Link to this page


Permanent link

Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..

Short link

Use the short link to share your document on Twitter or by text message (SMS)

HTML Code

Copy the following HTML code to share your document on a Website or Blog

QR Code

QR Code link to PDF file 07d0c77d5987f908461f9f7c33741941.pdf